Table 3.
Outcomes of younger (aged <60 years) Black and White acute myeloid leukemia patients treated on the CALGB/Alliance study protocols
| Outcome | Black patients n=72 |
White patients n=777 |
Pa |
|---|---|---|---|
| Early death | 7 (10) | 46 (6) | .20 |
| Complete remission | 51 (71) | 554 (71) | 1.00 |
| Relapse rate, n (%) | 36 (71) | 328 (59) | 0.14 |
| Disease-free survival | 0.02 | ||
| Median, years | 0.8 | 1.4 | |
| Disease-free at 3 years, % (95% CI) | 25 (15–38) | 38 (34–42) | |
| Overall survival | 0.02 | ||
| Median, years | 1.2 | 1.8 | |
| Alive at 3 years, % (95% CI) | 29 (19–40) | 42 (38–45) |
Abbreviations: CI, confidence interval.
Note. The median number of cycles of consolidation chemotherapy was 2 (range, 1–4) for Black and 1 (range, 1–4) for White patients (P=0.09).
a
P-values for early death and complete remission are from Fisher’s exact test, P-values for the time to event variables are from the log-rank test and compare the two groups: black and white AML patients.